<DOC>
	<DOCNO>NCT00338780</DOCNO>
	<brief_summary>The aim investigate whether Lamivudine 100mg daily effective long term treatment HBeAg negative chronic HBV infect patient active liver disease Asia</brief_summary>
	<brief_title>Trial Lamivudine Treatment HBeAg Negative Chronic Hepatitis B Patients ( Asia )</brief_title>
	<detailed_description>Recent study prove lamivudine potent antiviral drug suppress viral replication improve hepatic necro-inflammation minimal adverse effect HBeAg positive chronic hepatitis B patient . The efficacy lamivudine HBeAg positivce Asian patient weel establish . However , evidence HBeAg negative patient limited . In absence HBeAg seroconversion , guidance clinical management HBeAg negative hepatitis B patitents treat lamivudine data efficacy lamivudine control pre-core HBV disease long-term still need . Existing data HBeAg negative/ HBV DNA positive HBV demonstrate clear statisticallysignificant serological benefit lamivudine placebo treatment . Limited sustained response observe post-treatment follow one year treatment period . Whether result apply patient Asia uncertain . This study therefore intend assess te efficacy profile extend treatment period Asian population .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Age= &gt; 18 year HBsAg positive HBeAg negative least 6 month prior screen Serum HBVDNA postiviet , HBeAg negative HBeAb positive timepoint least one occasion last 6 month ALT &gt; 1.5 10 x upper limit normal least two occasion within previous 6 month screen , ALT &gt; upper limit normal least one biochemical flareup ( ALT &gt; 200IU/l ) last 12 month . Informed writted consent Liver biopsy material/ slide take within previous 12 month , least 5 month previous antiviral treatment show evidence active liver disease ( ie . evidence necroinflammatory activity ) Written informed consent Hepatocellular carcinoma ALT &gt; 10xULN screen history acute exacerbation lead transient decompensation Serum hepatitis C , hepatitis D HIV Decompensated liver desease indicate follow : serum bilirubin &gt; 3mg/dL , prothrombin time &gt; =2 second prolonged upper limit reference range , serum albumin &lt; 28g/L , history variceal haemorrhage , presence intractable ascites screen assessment . Encepalopathy Planned liver transplantation previous liver transplantation Evidence autoimmune hepatitis Amylase and/ lipase &gt; 2 time upper limit reference range Serum creatinine &gt; 1.5 time upper limit reference range Haemoglobin &lt; 11g/dL WBC count &lt; 3x10^9/L Platelets &lt; 100x10^9 Serious concurrent medical illness hepatitis B Use immunosuppressive therapy , immunomodylatory therapy chronic antiviral thgerpay agent within previous 6 month study Previous treatment lamivudine famciclovir within last 6 month History hypersensitivity nucleoside analogues Women childbearing potential practising adequate contraception Pregnancy lactation Receipt investigational drug within 30 day first dose study drug ChildPugh class B C cirrhosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>HBeAg negative</keyword>
</DOC>